Compare Moderna, Inc. (MRNA) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Moderna, Inc. trades at $221.51 (market cap $90.35B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $37.8 (market cap $63.89B). The key difference: Moderna, Inc. is the larger of the two by market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays a 2.47% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | RELX | |
|---|---|---|
Market Cap | $90.35B | $63.89B |
Volume | 16,579,584 | 2,760,502 |
Sector | Health | Industrials |
52-Week High | $226.30 | $46.80 |
52-Week Low | $22.36 | $27.73 |
Typical Hold Time | 59 Days | — |
Enterprise Value | $86.50B | $75.40B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative net income margins (-142.58%) and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock has rallied over 500% in 2026, creating valuation concerns with a P/S ratio of 40.29.
While Nasdaq inclusion and cancer vaccine pipeline progress offer upside potential, Moderna's high valuation and persistent losses present significant risk. Analyst consensus is mixed with a $115.70 price target below current levels, indicating cautious sentiment despite recent momentum. Investors face tension between growth prospects and financial sustainability.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →
